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a  b  s  t  r  a  c  t
Vulvovaginal candidiasis (VVC) is an infection of the genital mucosa caused by different
species of the genus Candida. Considering the lack of data on this topic in the south of Brazil,
this study aimed to assess the prevalence of Candida spp. in the cervical-vaginal mucosa of
patients treated at a university hospital in southern Rio Grande do Sul, as well as the eti-
ology  and the susceptibility of the isolates against ﬂuconazole, itraconazole, miconazole
and  nystatin. Samples were collected at the gynecology clinic of the Federal Hospital of the
University of Rio Grande, and the isolates were identiﬁed using phenotypic and biochemical
tests. The susceptibility analysis was performed according to the CLSI M27-A2 protocol. Of
the  263 patients included, Candida spp. was isolated in 27%, corresponding to a prevalence
of  approximately 15% for both VVC and colonization. More than 60% of the isolates were
identiﬁed as Candida albicans; C. non-albicans was isolated at a rate of 8.6% in symptomatic
patients and 14.3% in asymptomatic patients. The prevalence of resistance against ﬂucona-
zole and itraconazole was 42% and 48%, respectively; the minimal inhibitory concentration
of  miconazole ranged from 0.031 to 8 g/mL, and that of nystatin ranged from 2 to >16 g/mL.
The  high rate of resistance to triazoles observed in our study suggests the necessity of the
association of laboratory exams to clinical diagnosis to minimize the practice of empirical
treatments that can contribute to the development of resistance in the isolates.©  2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
s arti
endogenously due to predisposing factors that favor yeastan  open acces
ntroductionulvovaginal candidiasis (VVC) is characterized by an infec-
ion of the genital mucosa by Candida yeasts, which mainly
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undertakes the vulva and the vagina. The disease occursicina, Universidade Federal do Rio Grande, Rio Grande, RS, Brazil.
multiplication. Signs and symptoms such as itching, burn-
ing, cracking, erythema and vulvar edema, leukorrhea and
the presence of whitish plaques on the vaginal mucosa
lsevier Editora Ltda. This is an open access article under the CC
.
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are common.1 VVC is considered the second most common
cause of genital infection in women of reproductive age, and
although it represents a problem of global importance in pub-
lic health, its exact incidence is unknown.2,3
Risk factors for vulvovaginitis include pregnancy, use
of oral contraceptives, genetic predisposition, and previous
antibiotic therapy, among others. The incidence of infection,
as well as the increase in colonization of the mucosa by the
yeast, is also higher in women with diabetes due to their
higher glycogen levels and in those with HIV due to immune
suppression.4,5
Studies show that 70–75% of all women of reproductive age
develop at least one case of VVC during their lifetime.6,7 The
recurrence rate is 40–50%, and approximately 5–8% develop
recurrent vulvovaginal candidiasis (RVVC), which is charac-
terized by four or more  episodes of disease over a period of
twelve months.6–8
The main etiologic agent is Candida albicans, accounting for
70–90% of VVC cases.7,8 Among the non-albicans species C.
glabrata is highlighted7–9 due to its prevalence and resistance
to azoles.10,11
An increasing number of Candida spp. clinical isolates are
resistant to antifungal agents routinely used for the treat-
ment of VVC. In addition, studies in different regions of Brazil
suggest that geographical factors interfere in the prevalence
of Candida species as well as in the sensitivity of isolates to
antifungals.1,11–13 Considering this and the lack of data on
this topic in Rio Grande do Sul, this study aimed to iden-
tify the prevalence of Candida spp. isolated from the vaginal
mucosa of patients with and without vulvovaginitis treated
at a university hospital in extreme southern Brazil, as well as
the susceptibility of these isolates to four antifungals used in
gynecological routines.
Materials  and  methods
The study included 263 patients attended on from April 2013 to
October 2014 at the gynecology clinic of the University Hospi-
tal of the Federal University of Rio Grande (FURG) – Rio Grande
do Sul – Brazil. The women agreed to participate by signing the
Clariﬁed Informed Consent form. The sample size, calculated
using Epi Info 6.0 and considering a prevalence of 30%, a con-
ﬁdence level of 99%, maximum permissible error of 20% and
losses of 10%, was estimated to be a sample of 249 patients.
During the gynecological exam, a sample of cervical-
vaginal mucosa was collected using a sterile brush, which
was stored in sterile tubes containing PBS and kept refriger-
ated until processing. The sample was sent to the Mycology
Laboratory of the Medicine Faculty from FURG, where it
was processed within 12 h. The cultures were processed
in Sabouraud agar with chloramphenicol 0.01% (SCl) and
incubated at 37 ◦C for seven days with daily assessment of
growth. The yeasts were identiﬁed using phenotypic tests such
as micromorphology, chromogenic medium (CHROM Agar
Candida®), germ tube test, and microculture in agar corn-
meal and were conﬁrmed by biochemical automated method
(VITEK® 2). Each isolate was maintained on potato dextrose
agar (PDA) in the mycology collection at room temperature b i o l o g y 4 8 (2 0 1 7) 145–150
under freezing at −20 ◦C in saline with 30% glycerol for subse-
quent susceptibility testing.
The variables evaluated in the study were obtained by self-
administered pre-coded questionnaire and included age, skin
color, educational level, marital status, family income, HIV
infection status, pregnancy, contraception and vaginal pH at
the time of sample collection. Signs and symptoms assessed
during the gynecological exam were used to consider women
as colonized or presenting VVC, the latter being those that had
leukorrhea, pruritus, edema and/or vulvovaginal erythema
associated with the presence of whitish plaques in the mucosa
and the isolation of Candida spp. in mycological cultivation.
The in vitro susceptibility analysis of clinical isolates was
performed by broth microdilution using the M27-A2 standard
protocol CLSI (2002).14 For the standardization of fungal inocu-
lum, isolates were subcultured on PDA for 24 h at 37 ◦C, young
colonies were homogenized in sterile saline, and the turbidity
was adjusted to 0.5 on the McFarland scale by spectrophoto-
metry (530 nm)  to obtain a concentration of 1–5 × 106 CFU/mL.
Then, a dilution was performed at 1:100 and 1:20 in RPMI 1640,
resulting in a concentration of 5 × 102 to 2.5 × 103 CFU/mL. The
inoculum concentration was conﬁrmed using the Pour-plate
technique. The susceptibility test was performed at concen-
trations of 64 g/mL to 0.125 g/mL for ﬂuconazole and at
concentrations ranging from 16 g/mL to 0.031 g/mL for itra-
conazole, miconazole and nystatin.
The 96-well microplates were ﬁlled with 100 L of the
antifungal concentrations and 100 L of inoculum and were
incubated at 37 ◦C for 48 h along with growth and sterility con-
trols. Each isolate was tested in duplicate, and the results were
visually evaluated by turbidity, comparing the fungal growth
in the well with the growth control. The minimum inhibitory
concentration (MIC) of ﬂuconazole, itraconazole and micona-
zole was one that inhibited 80% of yeast growth, and the MIC
of nystatin inhibited 100% of growth.
According to the MIC result for ﬂuconazole and itracona-
zole, the isolates were classiﬁed as S for sensitive, SDD for
sensitive dose-dependent and R for resistant, as established
by the cutoff point protocol M27-A2. For miconazole and nys-
tatin, the MIC50 and MIC90 were calculated corresponding to
the antifungal concentration capable of inhibiting the growth
of 50% and 90%, respectively, of the isolates tested. After read-
ing the results of MIC, 10 L of the solutions from the wells
related to concentrations higher than and equal to the MIC
were plated on a Petri dish containing agar SCl and were incu-
bated at 37 ◦C for 48 h to determine the fungicide minimum
concentration (FMC).
The study was conducted according to ethical principles
and was approved by the Research Ethics Committee of the
Federal University of Rio Grande (65/2012). The results were
compiled by conducting descriptive analysis of the data and
chi-square tests for categorical variables using SPSS 19.0®
software. p-values below 0.05 were considered statistically sig-
niﬁcant.Results
The study population consisted mostly of women who  had
partners (64.5%), had white skin color (65.3%), were pregnant
b r a z i l i a n j o u r n a l o f m i c r o b i 
Table 1 – Descriptive analysis of the study population
(n = 263) and the inﬂuence of the variables studied
(chi-square test) in the development of vulvovaginal
candidiasis (VVC) (n = 35).
Variables n (%) VVC (n) p value
HIV-positive 71  (27.1) 10 0.833
HIV-negative 191 (72.9) 25
Pregnant 158 (60.3) 26 0.069
Not pregnant 104 (39.7) 09
Skin color 0.542
White 160 (65.3) 20
Not white 85 (34.7) 13
Marital status 0.891
Without a partner 89 (35.5) 11
With partner 162 (64.5) 21
Educational level 0.326
8 years or less 131 (51) 20
9 years or more 126 (49) 14
Family income 0.577
Less than 1 wage 56 (21.3) 09
1–2 wages 86 (32.7) 12
2.1 or more 79 (30) 08
Contraception 0.599
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explained by cultural habits of different regions, especially inHormonal 135 (54.7) 20
Not hormonal 112 (45.3) 14
60.3%) and were HIV-negative (72.9%). The mean age was 28.5
ears and ranged from 12 and 68 years, with more  than 65% of
he women under 31 years of age (n = 176) and 54.7% (n = 135)
sing hormonal contraception (Table 1).
Of the 263 patients, Candida spp. was isolated in the myco-
ogical culture from cervical-vaginal samples in 27% (n = 71).
f these, vulvovaginal candidiasis was diagnosed in 49.3%
n = 35), resulting in a prevalence in the population of 13.3%.
he remaining 50.7% (n = 36) that had no signs or symptoms
f vulvovaginitis were classiﬁed as colonization cases.
The predominant species was Candida albicans in both
roups, corresponding to 62.9% (n = 22) of isolates originating
rom the group of women colonized and 74.3% (n = 26) from
he women with VVC. The other species identiﬁed colonizing
he vaginal mucosa of healthy women were C. glabrata in
4.3% (n = 5), followed by C. sphaerica in 8.6% (n = 3) and C.
arapsilosis complex in 2.9% (n = 1). Among cases of VVC by C.
on-albicans (n = 5), 8.6% (n = 3) were due to C. glabrata, 2.9%
n = 1) were due to C. parapsilosis complex, and 2.9% (n = 1) were
Table 2 – Results of the in vitro susceptibility test of Candida spp
antifungal agents. S-sensitive, SDD-sensitive dose-dependent a
Species Fluconazole Itracon
S
n (%)
SDD
n (%)
R
n (%)
S
n (%)
SD
n (
C. albicans (n = 37) 12 (32.4) 4 (10.8) 21 (56.8) 8 (21.6) 9 (2
C. glabrata (n = 6) 1 (16.7) 5 (83.3) – 1 (16.7) 2 (3
C. parapsilosis complex (n = 2) 2 (100) – – 1 (50) – 
C. tropicalis (n = 1) 1 (100) – – 1 (100) – 
C. sphaerica (n = 3) 3 (100) – – 3 (100) – 
Candida spp. (n = 1) 1 (100) – – – 1 (1o l o g y 4 8 (2 0 1 7) 145–150 147
due to C. tropicalis. In addition, 11.4% (n = 4) of the isolates from
colonization, and 11.4% (n = 4) of the etiologic agents of VVC
were identiﬁed only in general, being classiﬁed as Candida spp.
Regarding the variables analyzed, 82.4% (n = 28) of patients
diagnosed with VVC belonged to the group of women aged 30
years or younger (p = 0.047). For the other variables such as skin
color, marital status, educational level, family income, contra-
ception, pregnancy and HIV infection, there was no signiﬁcant
difference between the group of women with and without VVC
(Table 1). The same occurred with the vaginal pH at the time of
collection, in which 133 patients had pH ≤ 4.5, but only 14.3%
(n = 19) of them were diagnosed with VVC (p = 0.948).
Of the 71 clinical isolates of Candida spp., 50 were sub-
jected to in vitro susceptibility testing, 25 from healthy women
and 25 from women with VVC. Considering all the isolates,
regardless of species, the MIC to miconazole ranged from
0.031 to 8 g/mL, with MIC50 = 0.5 g/mL and MIC90 = 4 g/mL,
and the MIC to nystatin ranged from 2 to >16 g/mL, with a
MIC50 = 4 g/mL and MIC90 = 8 g/mL. Concerning ﬂuconazole
and itraconazole, resistance was observed in 42% and 48%,
respectively, of the isolates (Table 2). No signiﬁcant difference
in MIC values was observed between clinical isolates of VVC
and colonization. Concerning ﬂuconazole, 100% of the isolates
of C. albicans and C. glabrata showed an FMC > 64 g/mL, and for
itraconazole, 100% of C. glabrata and 97% of C. albicans showed
an FMC > 16 g/mL (Table 3).
Discussion
The present study provides data about Candida spp. isola-
tion from the vulvovaginal mucosa of women in southern Rio
Grande do Sul, Brazil. We  detected the yeast in 27% of the study
population, corresponding to a prevalence of approximately
13% both for colonization and for vulvovaginal candidiasis.
Similar and lower rates of fungal isolation in women with and
without vulvovaginitis have been described in other studies of
the southern region: 11 and 24.7% in patients in the state of
Paraná,12–15 23.8% in patients in the state of Santa Catarina12
and 18.2% in the city of Santo Ângelo-RS,16 the latter being
the only study held in Rio Grande do Sul. These differences
in the isolation of Candida spp. from vaginal mucosa can beregard to hygiene practices, as this factor is directly related
to self-contamination because the yeast belongs to the nor-
mal  gastrointestinal tract microbiota.3,17,18 On the other hand,
. from colonized and/or VVC patients against four
nd R-resistant.
azole Miconazole Nystatin
D
%)
R
n (%)
MIC
(g/mL)
MIC50/MIC90
(g/mL)
MIC
(g/mL)
MIC50/MIC90
(g/mL)
4.3) 20 (54.1) 0.031–8.0 1.0/4.0 2.0–>16 4.0/8.0
3.3) 3 (50) 0.031–0.250 0.031/0.125 4.0–8.0 4.0/8.0
1 (50) 0.031–0.125 0.031/0.125 8.0 8.0/8.0
– 1.0 1.0/1.0 8.0 8.0/8.0
– 0.031 0.031/0.031 2.0–4.0 2.0/4.0
00) – 0.5 0.5/0.5 2.0 2.0/2.0
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Table 3 – Fungicide Minimum Concentration (FMC) results of the four antifungals tested against Candida spp. isolated
from colonized and/or VVC patients.
Species Fluconazole Itraconazole Miconazole Nystatin
FMC
(g/mL)
FMC50/
FMC90
(g/mL)
FMC
(g/mL)
FMC50/
FMC90
(g/mL)
FMC
(g/mL)
FMC50/
FMC90
(g/mL)
FMC
(g/mL)
FMC50/
FMC90
(g/mL)
C. albicans (n = 37) >64 >64/>64 16–>16 >16/>16 2.0–>16 >16/>16 4.0–8.0 8.0/80
C. glabrata (n = 6) >64 >64/>64 >16 >16/>16 16–>16 >16/>16 4.0–8.0 8.0/8.0
C. parapsilosis complex (n = 2) 4.0–>64 4.0/>64 2.0–>16 2.0/>16 2.0–>16 2.0/>16 8.0 8.0/8.0
C. tropicalis (n = 1) >64 >64/>64 >16 >16/>16 >16 >16/>16 8.0 8.0/8.0
.0 C. sphaerica (n = 3) 1.0–>64 1.0/>64 0.031–1
Candida spp. (n = 1) >64 >64/>64 1.0 
similar studies in northeastern Brazil show fungal isolation in
women with and without vulvovaginitis of up to 46%.1,17,19,20 It
is assumed that other factors besides those mentioned above
may explain the high prevalence of Candida spp. in this region,
such as weather conditions and social and environmental fac-
tors that are favorable to the reproduction of yeast.20
The rate of colonization of 13.7% observed in our study is
consistent with the literature,3,9 which describes that Can-
dida spp. is part of the genital microbiota of up to 30%
of healthy women.1,18 Whereas the disease occurs endoge-
nously, is important to differentiate between the colonization
and infection of the vaginal mucosa.3,18
Ferrazza and co-workers12 found a VVC prevalence of 19.2%
in Santa Catarina and of 9.3% in Paraná; these data are sim-
ilar to the prevalence of VVC found in our study.12 However,
it is below the 69% found by Holanda and co-workers17 in a
study conducted in Natal, the 47.9% found by Andrioli and co-
workers1 in Bahia, the 42.7% described by Sá and co-workers20
in Maranhão and the 39.6% found by Dias and co-workers7 in
Mato Grosso. Considering that this disease is opportunistic,
this discrepancy may be related to several factors related to
the etiologic agent, the species distribution and/or virulence
of the strains, the immune status of the host, or the environ-
ment, which inﬂuences the maintenance of temperature and
humidity conducive to fungal proliferation.1,12,20,21
The differences in geographical location should be consid-
ered among the epidemiologic factors that also interfere in the
prevalence of Candida spp. isolated from vaginal mucosa.12 In
this study, C. albicans was predominant, accounting for over
60% of the isolates both in colonized patients and in those
with VVC. In fact, this species is the most pathogenic of the
gender, being related to most cases of VVC described, and
generally represents more  than half of the isolates identiﬁed
in other studies.7,15,16,22 Ferraza and co-workers12 described
the identiﬁcation of this species in Santa Catarina in 100%
and 72% of isolates from the asymptomatic and symptomatic
patients, respectively, and in 66.7% of patients with VVC in
state of Paraná. Similarly, Camargo and co-workers16 identi-
ﬁed C. albicans in more  than 80% of the isolates from patients
with and without VVC in Santo Ângelo-RS.
Approximately 25% of cases of VVC were caused by
non-albicans species in our study. Among these, C. glabrata,
described as the second most important species in cases
of VVC due to its frequency10,12,15,18,23 and greater resis-
tance to antifungals10,22,24 was found in 8.6% of symptomatic
patients and in 14.3% of colonized patients in our study, which0.031/1.0 0.031–2.0 0.031/2.0 2.0–4.0 4.0/4.0
1.0/1.0 8 8.0/8.0 2.0 2.0/2.0
highlights the importance of laboratory tests for correct iden-
tiﬁcation of the etiologic agent, although the clinical diagnosis
of the disease is easily performed and commonly applied.2,25
Regarding the variables studied, the largest number of
patients with VVC was from the group of women younger than
31 years, being within the reproductive age group,3 which is
considered a risk factor for VVC due to sexual activity.8 How-
ever, this difference in age between the group of women with
VVC and the otherwise healthy group was not detected by
other authors.1,17,19,23 Similarly, use of hormonal contracep-
tion or intrauterine devices, vaginal pH ≤ 4.5, pregnancy and
HIV infection, which are considered as risk factors for the
development of VVC3,5,20,26 were not signiﬁcantly associated
with VVC infection in our study. This discrepancy may be due
to the small number of women with VVC in our study (n = 35),
which does not allow for a robust statistical analysis for risk
factors for the disease.
According to our study as well as that of Rodrigues and
co-workers23 the other variables such as marital status, educa-
tional level and skin color do not exert signiﬁcant inﬂuence on
the development of VVC. Moreover, Álvares and co-workers4
state that the vaginal microbiota of black women has a lower
incidence of bacterial species, and there would thus be a
decrease in natural defenses against fungal growth, predis-
posing them to infection by Candida spp.4,20
In vitro studies have shown different resistance rates
of Candida spp. from the vaginal mucosa to the azole
drugs commonly used in the treatment and prophylaxis of
VVC.7,8,10,11,13,22,24,27,28 Concerning ﬂuconazole, the resistance
rates range from 0.8% to 12.5%.7,10,11,24,28 These values are con-
siderably lower than the results found in our study, in which
42% of the isolates were resistant to ﬂuconazole. However,
Dalazen and co-workers22 in a study conducted in Santa Cata-
rina, found 100% of ﬂuconazole resistance. With respect to
itraconazole, resistance rates described in other studies range
from 1.9 to 43%,10,13,27,28 also lower than the 48% found in our
study. In addition to the high rate of resistance to ﬂucona-
zole and itraconazole observed, the FMC  of more  than 90% of
the isolates was greater than the maximum antifungal con-
centration tested. Therefore, there is a tendency to avoid the
prophylactic use of low doses of antifungals in gynecological
routines to prevent the emergence of drug-resistant isolates.2Another group of azole drugs used for topical treatment
of VVC is miconazole.22 In our study, the MIC  for this drug
ranged from 0.031 to 8 g/mL. These data were similar to those
found in a study by Choukri and co-workers29 in which the
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IC  to miconazole varied between 0.015 and 8 g/mL and
n a study by Richter and co-workers10 in which the varia-
ion was between 0.007 and 4 g/mL. Moreover, Dalazen and
o-workers22 found a variation in the MIC  of miconazole of
etween 0.097 and ≥100 g/mL. The different genotypes of the
ame species may be signiﬁcantly different in their suscepti-
ility to azoles.27
The polyenic agents are another group of drugs used for
he treatment of VVC; this group includes nystatin, which is
he most used in Brazil and is freely available in the Uniﬁed
ealth System (SUS) in Brazil.30 The MIC  of nystatin found
n our study ranged from 2 to >16 g/mL; however, in a study
y Choukri and co-workers,29 the MIC  varied between 1 and
 g/mL, and in a study by Richter and co-workers,10 the
oncentration ranged from 1 to 16 g/mL. Knowledge of the
atterns of susceptibility to typical drugs in isolates from dif-
erent regions will allow for the rationalization of the empirical
se of antifungal agents, thus contributing to the control of the
solated resistance to drugs.2
Our results will encourage the development of other stud-
es related to the resistance mechanisms of these yeasts and
lso of clinical trials in the hospital to determine whether the
igh resistance to antifungals detected in vitro actually corre-
ponds to therapeutic failure.
According to this data discrepancies and the lack of epi-
emiological data in the state of Rio Grande do Sul, the present
tudy has been collaborating with local epidemiology, eluci-
ating the etiological factors of VVC and warning of the high
esistance rates found in vitro in Candida spp. isolates evalu-
ted.
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